Skip to main content

Table 3 Comparison between results of neurocognitive scales in both groups

From: Relation of serum level of tumor necrosis factor-alpha to cognitive functions in patients with Parkinson’s disease

Mean ± SD

Patients group

(n = 30)

Control group

(n = 30)

p-value

ACE-III

81.40 ± 5.957

94.33 ± 3.066

 < 0.001**

Attention ACE

17.13 ± 0.900

17.53 ± 0.571

0.044*

Memory ACE

19.63 ± 4.115

24.30 ± 1.119

 < 0.001**

Verbal fluency ACE

6.87 ± 2.609

12.67 ± 0.959

 < 0.001**

Language ACE

24.93 ± 1.311

25.23 ± 0.679

0.272

Visuospatial ACE

13.33 ± 1.863

15.23 ± 0.817

 < 0.001**

Trail making test B

239.14 ± 53.728

103.10 ± 24.669

 < 0.001**

  1. ACE-III Addenbrooke’s Cognitive Examination
  2. *Significant, ** highly significant